Citations

Clear

4610 citation(s) found for "Lu, Brian".

Epigenetic disease markers in primary sclerosing cholangitis and primary biliary cholangitis—methylomics of cholestatic liver disease
Juran, Brian D., McCauley, Bryan M. , Atkinson, Elizabeth J. , Schlicht, Erik M., Bianchi, Jackie K., Vollenweider, Jason, Ye, Hong , LaRusso, Nicholas F. , Gores, Gregory J. , Sun, Zhifu , Gores, Gregory J. , Vollenweider, Jason M, Sun, Zhifu , LaRusso, Nicholas F , Lazaridis, Konstantinos N.

Mayo Clinic

Hepatology Communications | July 18, 2024 | Volume: 8 | Issue: 8 | Pages: No page available

10.1097/hc9.0000000000000496 | PMID 39023332 Get It

Background: The epigenome, the set of modifications to DNA and associated molecules that control gene expression, cellular identity, and function, plays a major role in mediating cellular responses to outside factors. Thus, evaluation of the epigenetic state can provide insights into cellular adaptions occurring over the course of disease. Methods: We performed epigenome-wide association studies of primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) using the Illumina MethylationEPIC Bead Chip. Results: We found evidence of increased epigenetic age acceleration and differences in predicted immune cell composition in patients with PSC and PBC. Epigenetic profiles demonstrated differences in predicted protein levels including increased levels of tumor necrosis factor receptor superfamily member 1B in patients with cirrhotic compared to noncirrhotic PSC and PBC. Epigenome-wide association studies of PSC discovered strongly associated 5′-C-phosphate-G-3′ sites in genes including vacuole membrane protein 1 and SOCS3, and epigenome-wide association studies of PBC found strong 5′-C-phosphate-G-3′ associations in genes including NOD-like receptor family CARD domain containing 5, human leukocyte antigen-E, and PSMB8. Analyses identified disease-associated canonical pathways and upstream regulators involved with immune signaling and activation of macrophages and T-cells. A comparison of PSC and PBC data found relatively little overlap at the 5′-C-phosphate-G-3′ and gene levels with slightly more overlap at the level of pathways and upstream regulators. Conclusions: This study provides insights into methylation profiles of patients that support current concepts of disease mechanisms and provide novel data to inspire future research. Studies to corroborate our findings and expand into other -omics layers will be invaluable to further our understanding of these rare diseases with the goal to improve and individualize prognosis and treatment.
Effect of Antibiotic Therapy Before Arthrocentesis on Synovial Fluid Cell Count and Differential for Diagnosis of Native Joint Septic Arthritis
Khodadadi, Ryan B. , McHugh, Jack , Zein, Said El , Lahr, Brian D. , Yuan, Brandon J. , Saleh, Omar Abu , Suh, Gina A. , Tande, Aaron J. , Damronglerd, Pansachee, McHugh, Jack , El Zein, Said , Lahr, Brian , Yuan, Brandon , Abu Saleh, Omar , Suh, Gina A , Tande, Aaron , Khodadadi, Ryan B , Damronglerd, Pansachee

Mayo Clinic

Open Forum Infectious Diseases | July 18, 2024 | Volume: 11 | Issue: 7 | Pages: No page available

10.1093/ofid/ofae403 | PMID 39077054 Get It

Abstract We examined the effect of preoperative antibiotic exposure and duration on synovial fluid samples from patients with native joint septic arthritis of the hip/knee. While exposure before diagnostic arthrocentesis did not affect fluid parameters, increased duration was associated with a decreased total nucleated cell count, underscoring the complex antibiotic effects on synovial fluid parameters.
Implementation of peer comparison reporting and academic detailing sessions to reduce inappropriate antimicrobial prescribing rates in upper respiratory infections among family medicine prescribers
Burroughs, Brian , Carney, Christina , Burroughs, Brian T , Jensen, Kelsey

Mayo Clinic

BMJ Open Quality | July 17, 2024 | Volume: 13 | Issue: 3 | Pages: e002619

10.1136/bmjoq-2023-002619 | PMID 39019588 Get It

Endovascular Thrombectomy With and Without Preceding Thrombolysis in Posterior Circulation Stroke—Insights From STAR
Heide, Ev‐Christin , Brinjikji, Waleed , Chowdhry, Shakeel , Dumont, Travis M., Ernst, Marielle , Ezzeldin, Mohamad , Kan, Peter, Kim, Joon‐Tae , Moss, Mark, Polifka, Adam , Psychogios, Marios‐Nikos , Rai, Ansaar , Starke, Robert M. , Tanweer, Omar , Williamson, Richard A., Spiotta, Alejandro M , Maier, Ilko , Investigators, STAR, Kasab, Sami Al , Alawieh, Ali , Arthur, Adam Stephen , Crosa, Roberto , Cuellar, Hugo , Leacy, Reade De , Fragata, Isabel , Howard, Brian M , Jabbour, Pascal , Levitt, Michael R. , Mascitelli, Justin R , Matouk, Charles , Navía, Pedro , Osbun, Joshua W , Park, Min S. , Romano, Daniele G., Shaban, Amir , Williamson, Richard, Wolfe, Stacey Q , Yoshimura, Shinichi , Investigators, STAR

Mayo Clinic

Stroke: Vascular and Interventional Neurology | July 16, 2024 | Volume: 4 | Issue: 5 | Pages: No page available

10.1161/svin.124.001334 | PMID 41586281 Get It

Background Multiple randomized trials could not establish the noninferiority of endovascular thrombectomy (EVT) alone without preceding intravenous thrombolysis (IVT) or superiority of IVT followed by EVT in anterior circulation large‐vessel occlusion stroke. The role of prior IVT in posterior circulation large‐vessel occlusion remains controversial. Methods In this multicenter, retrospective study, patients with stroke with large‐vessel occlusion in the posterior circulation who received EVT alone or with IVT were selected from the stroke thrombectomy and aneurysm registry between 2013 and 2022. Effects of IVT followed by thrombectomy on favorable functional outcome (defined as modified Rankin scale≤3 at 90 days) and safety were investigated using multivariable logistic and linear regression models. Results Of the 588 included patients, 67% (n = 394) were treated with EVT alone and 29% (n = 170) with EVT after IVT, and 4% (n = 24) have missing values on this variable. Controlling for multiple confounding factors, IVT was not associated with a higher likelihood of favorable functional outcome at 90 days (odds ratio, 1.04 [95% CI, 0.52–2.09; P = 0.901). Thrombectomy alone did not show any safety advantages compared with those receiving IVT. Conclusion Similar functional outcomes and complication rates were seen in patients with posterior circulation large‐vessel occlusion treated with EVT alone versus EVT after IVT. Further prospective studies are required to determine the utility of IVT in posterior circulation stroke, especially in patients being directly admitted to thrombectomy centers.
The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder
Chung, Doreen E. , Dielubanza, Elodi , Enemchukwu, Ekene , Ginsberg, David A. , Linder, Brian J. , Rovner, Eric S., Souter, Lesley , Welk, Blayne , Linder, Brian J , Cameron, Anne P. , Helfand, Brian T. , Reynolds, William M. , Suskind, Anne M. , Takacs, Elizabeth B. , Smith, Ariana L.

Mayo Clinic

Neurourology and Urodynamics | July 16, 2024 | Volume: 43 | Issue: 8 | Pages: 1742-1752

10.1002/nau.25532 | PMID 39010271 Get It

AbstractPurposeThe purpose of this guideline is to provide evidence‐based guidance to clinicians of all specialties on the evaluation, management, and treatment of idiopathic overactive bladder (OAB). The guideline informs the reader on valid diagnostic processes and provides an approach to selecting treatment options for patients with OAB through the shared decision‐making process, which will maximize symptom control and quality of life, while minimizing adverse events and burden of disease.MethodsAn electronic search employing OVID was used to systematically search the MEDLINE and EMBASE databases, as well as the Cochrane Library, for systematic reviews and primary studies evaluating diagnosis and treatment of OAB from January 2013 to November 2023. Criteria for inclusion and exclusion of studies were based on the Key Questions and the populations, interventions, comparators, outcomes, timing, types of studies and settings (PICOTS) of interest. Following the study selection process, 159 studies were included and were used to inform evidence‐based recommendation statements.ResultsThis guideline produced 33 statements that cover the evaluation and diagnosis of the patient with symptoms suggestive of OAB; the treatment options for patients with OAB, including Noninvasive therapies, pharmacotherapy, minimally invasive therapies, invasive therapies, and indwelling catheters; and the management of patients with BPH and OAB.ConclusionOnce the diagnosis of OAB is made, the clinician and the patient with OAB have a variety of treatment options to choose from and should, through shared decision‐making, formulate a personalized treatment approach taking into account evidence‐based recommendations as well as patient values and preferences.
Find Your Perfect Match for Surgical Residency: Six Steps to Building your BRANDD from the Collaboration of Surgical Education Fellows
Woodward, John M. , Brian, Riley , Navarro, Sergio M. , Rodríguez, Jorge , Tate, Katrina, Sathe, Tejas , Oh, Mary H., Godley, Frederick A. , L’Huillier, Joseph C. , Lund, Sarah , Navarro, Sergio Michael , Anand, Ananya , Moreci, Rebecca , Naaseh, Ariana , Roshal, Joshua A. , Silvestri, Caitlin J. , Gan, Connie Y. , Thornton, Steven W. , Cloonan, Madeline R. , Weaver, Lauren

Mayo Clinic

Annals of Surgery Open | July 11, 2024 | Volume: 5 | Issue: 3 | Pages: e466

10.1097/as9.0000000000000466 | PMID 39310337 Get It

A phase 2 study of a brachyury‐targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma
Attia, Steven , Tine, Brian A. Van , Seetharam, ­Mahesh , Gafoor, Zarina, Heery, Christopher R., Pico-Navarro, Cesar, Adams, Tatiana , Van Tine, Brian A , Coté, Gregory M. , Conley, Anthony P. , Chen, Yen‐Lin

Mayo Clinic

Cancer | July 10, 2024 | Volume: 130 | Issue: 22 | Pages: 3845-3854

10.1002/cncr.35477 | PMID 38985843 Get It

AbstractBackgroundThis was a single‐arm, phase 2 clinical trial of Bavarian Nordic (BN)‐Brachyury vaccine plus radiotherapy (RT) designed to determine the objective response rate (ORR), progression‐free survival (PFS), and safety of the combination in chordoma.MethodsA total of 29 adult patients with advanced chordoma were treated with two subcutaneous priming vaccine doses of modified vaccinia Ankara‐Bavarian Nordic (MVA‐BN)‐Brachyury and one vaccine dose of fowlpox virus (FPV)‐Brachyury before RT. After RT, booster vaccinations were given with FPV‐Brachyury every 4 weeks for 4 doses, then every 12 weeks (week 110). A minimum RT dose of >8 Gy in one fraction for each target was required. Response was evaluated by modified Response Evaluation Criteria in Solid Tumors 1.1 (mRECIST), where only radiated lesions were considered targets, and by standard RECIST 1.1 in a subset of patients.ResultsTwo of 26 evaluable patients experienced durable partial response (PR) (ORR of 7.7%; 90% confidence interval [CI], 2.6–20.8]) by mRECIST 1.1. A total of 21 patients (80.8%; 90% CI, 65.4–90.3) had stable disease, and three patients (11.5%; 90% CI, 4.7–25.6) had progressive disease as best response per mRECIST 1.1. Median PFS was not reached during the study.ConclusionsThis trial confirms the safety of BN‐Brachyury and RT. Although the study did not meet the predefined study goal of four responses in 29 patients, we did observe two PRs and a PFS of greater than 2 years. For a vaccine‐based study in chordoma, an ultra‐rare disease where response rates are low, a randomized study or novel trial designs may be required to confirm activity.
Training and Verification Requirements for Interpretation of Cardiac CT and MRI: AJR Expert Panel Narrative Review
Morris, Michael F. , Ocazionez-Trujillo, Daniel , Ordovás, Karen , Ranganath, Praveen , Vargas, Daniel , Woodard, Pamela K. , Choi, Andrew , Rajiah, Prabhakar Shantha, Rajiah, Prabhakar , Budoff, Matthew J. , Ghoshhajra, Brian , Patel, Amit R.

Mayo Clinic

American Journal of Roentgenology | July 10, 2024 | Volume: 224 | Issue: 3 | Pages: No page available

10.2214/ajr.24.31524 | PMID 38984783 Get It

A multi‐institutional survey of apheresis services among institutions in the United States
Yurtsever, Nalan, Jacobs, Jeremy W. , Park, Yara A. , Lauro, Deisen, Torres, Sarina, Ward, Dawn C. , Stephens, Laura D. , Adkins, Brian D. , Yurtsever, Nalan , Stephens, Laura , Tormey, Christopher A , Adkins, Brian David , Jacobs, Jeremy W , Yurtsever, Nalan , Booth, Garrett S. , Schwartz, Joseph E. , Woo, Jennifer S. , Allen, Elizabeth S. , Tormey, Christopher A.

Mayo Clinic

Journal of Clinical Apheresis | July 9, 2024 | Volume: 39 | Issue: 4 | Pages: No page available

10.1002/jca.22138 | PMID 38979705 Get It

AbstractIntroductionApheresis practices in the United States (US) have not been comprehensively characterized to date. This study aimed to address this gap by evaluating apheresis therapy through a national survey.MethodsA multi‐institutional survey was conducted between April and July 2023. The survey, comprising 54 questions, focused on institutional demographics, procedures, equipment, staffing, training, and impacts of the Coronavirus Disease 2019 (COVID‐19) pandemic. Responses from 22 institutions, primarily academic medical centers, were analyzed.ResultsTherapeutic plasma exchange (TPE) was the most common procedure, followed by hematopoietic progenitor cell collection (HPC‐A) and red blood cell exchange (RCE). CAR‐T cell collections were widespread, with some institutions supporting over 30 protocols concurrently. Most sites used the Spectra Optia Apheresis System, were managed by a transfusion medicine service, and employed internal apheresis providers. Insufficient staffing levels, exacerbated by the COVID‐19 pandemic, were common and most often addressed using overtime.DiscussionThe survey highlighted the ubiquity of TPE, expanding cellular collections and staffing challenges. The role of apheresis in supporting cellular therapy, particularly in newly developing cell and gene therapies and clinical trials, was evident. Staffing issues during the pandemic emphasized the need for innovative recruitment strategies.ConclusionThis nationwide survey provides the most comprehensive analysis to date of apheresis practices in large US academic centers.
Predicting Response to Neuromodulators or Prokinetics in Patients With Suspected Gastroparesis Using Machine Learning: The “BMI, Infectious Prodrome, Delayed GES, and No Diabetes” Model
Takakura, Will , Surjanhata, Brian , McCallum, Richard W. , Schulman, Michael I., Wo, John M. , Sarosiek, Irene , Moshiree, Baha , Lee, Allen , Hasler, William L. , Lee, Allen A , Nguyen, Linda Anh B. , Parkman, Henry P. , Rao, Satish S.C. , Kuo, Braden

Mayo Clinic

Clinical and Translational Gastroenterology | July 8, 2024 | Volume: 15 | Issue: 9 | Pages: e1

10.14309/ctg.0000000000000743 | PMID 39320959 Get It

INTRODUCTION: Pharmacologic therapies for symptoms of gastroparesis (GP) have limited efficacy, and it is difficult to predict which patients will respond. In this study, we implemented a machine learning model to predict the response to prokinetics and/or neuromodulators in patients with GP-like symptoms. METHODS: Subjects with suspected GP underwent simultaneous gastric emptying scintigraphy (GES) and wireless motility capsule and were followed for 6 months. Subjects were included if they were started on neuromodulators and/or prokinetics. Subjects were considered responders if their GP Cardinal Symptom Index at 6 months decreased by ≥1 from baseline. A machine learning model was trained using lasso regression, ridge regression, or random forest. Five-fold cross-validation was used to train the models, and the area under the receiver operator characteristic curve (AUC-ROC) was calculated using the test set. RESULTS: Of the 150 patients enrolled, 123 patients received either a prokinetic and/or a neuromodulator. Of the 123, 45 were considered responders and 78 were nonresponders. A ridge regression model with the variables, such as body mass index, infectious prodrome, delayed gastric emptying scintigraphy, no diabetes, had the highest AUC-ROC of 0.72. The model performed well for subjects on prokinetics without neuromodulators (AUC-ROC of 0.83) but poorly for those on neuromodulators without prokinetics. A separate model with gastric emptying time, duodenal motility index, no diabetes, and functional dyspepsia performed better (AUC-ROC of 0.75). DISCUSSION: This machine learning model has an acceptable accuracy in predicting those who will respond to neuromodulators and/or prokinetics. If validated, our model provides valuable data in predicting treatment outcomes in patients with GP-like symptoms.